Wed. 21 Feb 2024, 8:32am ET
Benzinga
Biotech, News, General
- PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS
- Standard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progression
- Further analysis of PARADIGM is on track with neurofilament results expected in Q1 and TDP-43 and ProstaglandinJ2 biomarkers expected in the first half of 2024